Vasculitis & polymyalgia rheumatica
EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: 2022 update
Methodological detailsrecommendations, EULAR standardised operating procedures, systematic literature review, expert opinion (20 experts, 16 countries), EULAR task force: systematic literature review and opinion from 20 experts from 16 countries; existing recommendations modified and new ones created
- Recommendations
- EULAR standardised operating procedures
- Systematic literature review
- Expert opinion (20 experts, 16 countries)
- EULAR task force: systematic literature review and opinion from 20 experts from 16 countries; existing recommendations modified and new ones created
Recommendations
As issued by the authors
Biopsies and ANCA testing to assist in establishing a diagnosis of AAV
Remission induction in life-threatening or organ-threatening AAV: high-dose GC combined with either RTX or CYC
Taper GC to a target of 5 mg prednisolone equivalent/day within 4-5 months
Avacopan may be considered as part of a strategy to reduce GC exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
Plasma exchange may be considered in rapidly progressive glomerulonephritis
Remission maintenance of GPA/MPA: RTX
Relapsing or refractory EGPA: mepolizumab
AZA and MTX are alternatives to biologics for remission maintenance in AAV
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →